

ASX Company Announcement

Dimerix Bioscience receives Australian patent grant for Combination Therapy

9 June 2015 - Further to the previous announcements by the Company regarding its proposed acquisition of Dimerix Bioscience, the Board of Sun Biomedical wishes to advise the market regarding significant progress in development and commercialization of DMX-200, a lead candidate in development for Chronic Kidney Disease (CKD).

The management of Dimerix Bioscience has advised Sun Biomedical that Australian patent No. 2012206945 entitled "Combination Therapy" in the name of Dimerix Bioscience Ltd has been granted by the Australian Patent Office. The patent covers the Dimerix Chronic Kidney Disease therapy, DMX-200. This grant marks the completion of the first substantive examination for this family.

An application for examination under the US Patent Prosecution Highway has been filed in relation to the US equivalent application, 13/979,127. Upon acceptance into the US patent prosecution highway, applications are placed in a "fast tracked" queue for examination.

Dimerix Bioscience is currently recruiting in to Phase II clinical study in patients with CKD. There are 26 million people in US and 1.7 million in Australia aged 18 years and over that have indications of CKD. With limited treatment options that can stop progression of this disease and severe associated complications, DMX-200 could become long awaited solution for suffering patients in a form of an oral medication. Upon successful results from the Phase II study, expected during the first half of 2016, Dimerix Bioscience intends to pursue the pathway of registration of DMX-200 initially for an orphan indication of CKD, such as Nephrotic Syndrome.

Sun Biomedical remains on track to complete the acquisition of Dimerix Bioscience and the Shareholder meeting to vote on the acquisition is scheduled for 30 June 2015.

"This is very positive news for our shareholders" said Howard Digby, Chairman of Sun Biomedical. "Not only is Dimerix embarking on a phase II clinical program, there is a pipeline of combination therapy applications to follow. The granting of the Australian Patent for DMX200 and the fast track process in the USA are important steps along the path to commercial partnerships and to ultimately make a positive impact on the lives of millions of people with CKD."

-end-

Howard Digby
Executive Chairman
+61 434 987 750